ALNY Trading Analysis - 10/23/2026 12:47 PM — TRU-SENTIMENT

News Headlines & Context

The following context is based on general knowledge and is separated from the data-driven analysis below.

• Alnylam Pharmaceuticals (ALNY) recently presented positive interim Phase III data for a RNAi therapeutic targeting cardiovascular disease, reinforcing its pipeline leadership.
• The company announced expansion of a global commercialization partnership, potentially broadening royalty streams beyond current products.
• Biotech sector volatility increased amid FDA commentary on accelerated approval pathways, creating sector-wide uncertainty.
• No confirmed near-term earnings date was flagged in general knowledge, but historical fiscal year-end is December, with investor focus on year-end guidance.
• Context: Pipeline wins support long-term fundamentals, but the embedded technical data shows a downtrend from September highs, suggesting news optimism is not yet reflected in price.

Fundamental Analysis

Based strictly on the provided FUNDAMENTALS data:

• Trailing P/E is 41.70 and trailing EPS is 5.53; no forward P/E, PEG, or price-to-book provided.
• Market cap is 30,207,381,750.00 with shares outstanding of 133,809,000.00.
• Dividend yield is 0.00; no dividend rate or ex-dividend date.
• Beta is 0.94 (less volatile than market); 52-week high 485.36, 52-week low 197.81 (current price 225.75 is near 52-week low zone).
• Institutional ownership is 95.00%, average volume 1,247,000.00.
• Historical volatility is 41.63%; fiscal year end 2025-12-01.
• Revenue growth, margins, ROE, debt/equity, and free cash flow are null — not available in data.
• Analyst target mean price and recommendation key are null — no consensus context.
• Fundamentals show high institutional backing and premium P/E, but missing profitability trends diverge from the bearish technical picture (price below SMAs).

Current Market Position

Current price from indicators: 225.75. Daily history shows 2026-10-22 close at 225.75 after opening 224.92, high 229.82, low 223.76, volume 1,724,780 (above 20-day avg of 887,344.00).

Minute bars (2026-10-21 09:30 to 2026-10-22 15:55): Start 228.61, end 226.90; last 5 bars show climb from 225.61 to 226.90 on rising volume (126,590 at final bar). Intraday late-session momentum is mildly positive but overall 2-day close fell from 225.26 to 225.75.

Technical Analysis

• Price below SMA 5 (229.29), SMA 20 (232.40), and SMA 50 (239.17) — bearish alignment, no bullish crossover.
• RSI 55.31: neutral-to-slightly bullish momentum, not overbought.
• MACD -3.90 below signal -3.12, histogram -0.78: bearish momentum persisting.
• Bollinger: middle 232.40, upper 254.85, lower 209.95; price near lower-middle, no squeeze detected.
• 30-day range high 257.27, low 215.46; price at 225.75 is 18.7% above low, 67.5% down from high.

True Sentiment Analysis (Delta 40-60 Options)

Options flow via tru-sentiment methodology (Delta 40-60 only):

Call Volume: 27,740.00 (100.00%) Put Volume: 0.00 (0.00%) Total: 27,740.00

• Sentiment: Bullish (4 call trades, 0 put trades, 14 call contracts).
• Pure directional conviction shows 100% call dollar volume — strong near-term bullish expectation from directional options.
• Divergence: Technicals bearish (price below SMAs, MACD negative) but options sentiment bullish per spread recommendation logic.

Key Price Levels (Observational Only)